PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	glutamic pyruvic transaminase, soluble	Mus musculus	222-246
32026851-6	2020	RKI-1447 reduced the histological changes in the mouse model of NAFLD in mice fed a high-fat diet and significantly inhibited the generations of triglyceride, IL-6, and TNF-alpha.	RKI-1447	0-8	interleukin 6	Mus musculus	159-163
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	glutamic pyruvic transaminase, soluble	Mus musculus	248-251
32026851-6	2020	RKI-1447 reduced the histological changes in the mouse model of NAFLD in mice fed a high-fat diet and significantly inhibited the generations of triglyceride, IL-6, and TNF-alpha.	RKI-1447	0-8	tumor necrosis factor	Mus musculus	169-178
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	254-276
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	ras homolog family member A	Homo sapiens	138-142
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	278-281
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	interleukin 6	Mus musculus	317-330
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	144-149
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	interleukin 6	Mus musculus	332-336
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	tumor necrosis factor	Mus musculus	339-366
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	151-156
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	tumor necrosis factor	Mus musculus	368-377
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	toll like receptor 4	Homo sapiens	158-178
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	toll like receptor 4	Homo sapiens	180-184
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	TANK binding kinase 1	Homo sapiens	189-193
32026851-7	2020	RKI-1447 reduced the levels of oxidative stress in HepG2 cells treated with oleic acid and significantly down-regulated the expression of RhoA, ROCK1, ROCK2, toll-like receptor 4 (TLR4), p-TBK1, and p-IRF3.	RKI-1447	0-8	interferon regulatory factor 3	Homo sapiens	201-205
32026851-8	2020	RKI-1447 treatment also inhibited RhoA expression.	RKI-1447	0-8	ras homolog family member A	Homo sapiens	34-38
32026851-9	2020	CONCLUSIONS In a mouse model of NAFLD, RKI-1447 inhibited ROCK and modulated insulin resistance, oxidative stress, and inflammation through the ROCK/TLR4/TBK1/IRF3 pathway.	RKI-1447	39-47	toll-like receptor 4	Mus musculus	149-153
32026851-9	2020	CONCLUSIONS In a mouse model of NAFLD, RKI-1447 inhibited ROCK and modulated insulin resistance, oxidative stress, and inflammation through the ROCK/TLR4/TBK1/IRF3 pathway.	RKI-1447	39-47	TANK-binding kinase 1	Mus musculus	154-158
32026851-9	2020	CONCLUSIONS In a mouse model of NAFLD, RKI-1447 inhibited ROCK and modulated insulin resistance, oxidative stress, and inflammation through the ROCK/TLR4/TBK1/IRF3 pathway.	RKI-1447	39-47	interferon regulatory factor 3	Mus musculus	159-163